Finch Therapeutics Group, Inc.

$7.45+0.00%(+$0.00)
TickerSpark Score
47/100
Weak
60
Valuation
20
Profitability
55
Growth
68
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FNCH research report →

52-Week Range39% of range
Low $2.00
Current $7.45
High $16.10

Companywww.finchtherapeutics.com

Finch Therapeutics Group, Inc. , a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus.

CEO
Matthew Blischak
IPO
2021
Employees
1
HQ
Somerville, MA, US

Price Chart

-43.82% · this period
$14.56$10.38$6.21May 16Nov 14May 18

Valuation

Market Cap
$11.96M
P/E
-0.86
P/S
0.00
P/B
1.32
EV/EBITDA
-2.15
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-86.83%
ROIC
-38.62%

Growth & Income

Revenue
$0 · -100.00%
Net Income
$-13,877,000 · 81.44%
EPS
$-8.64 · 81.46%
Op Income
$-18,859,000
FCF YoY
0.00%

Performance & Tape

52W High
$16.10
52W Low
$2.00
50D MA
$12.77
200D MA
$12.96
Beta
1.17
Avg Volume
3.65K

Get TickerSpark's AI analysis on FNCH

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Jun 7, 24SMISEK JEFFERY Aother383
Jun 7, 24SMISEK JEFFERY Aother384
May 20, 24SMISEK JEFFERY Aother3,750
Mar 28, 24SMISEK JEFFERY Asell1,600
Mar 28, 24SMISEK JEFFERY Asell6,642
Nov 22, 23SMISEK JEFFERY Asell1,470
Jun 9, 23Blischak Matthew P.other962,899
Jun 8, 23Blischak Matthew P.other962,899
Jun 8, 23Lange Christian H.other10,000
Jun 8, 23SMISEK JEFFERY Aother10,000

Our FNCH Coverage

We haven't published any research on FNCH yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate FNCH Report →

Similar Companies